Pioneering
Antibody Therapeutics for Cardiovascular Disease

Laurel is a preclinical biotechnology company developing next-generation antibody therapeutics for cardiovascular disease.

Our platform combines AI-enabled design with immune-derived discovery to generate modular single-domain and monoclonal formats that address crosstalk among cardiovascular, inflammatory, and metabolic pathways, with the goal of reducing patients’ at-home pharmacy burden.

Built as a plug-and-play engine, our approach supports multiple targets, formats, and combinations.

Contact Us

NEWS & UPDATES

September 2025

LabCentral’s Ignite Golden Tickets support the next generation of powerhouse biotech companies by giving high-potential founders access to resources and networks to advance breakthrough science. This year, five tickets will be awarded to biotech entrepreneurs advancing high-impact innovations for human health, with a focus on emerging founders who have had limited access to industry networks and infrastructure. We’re honored to be a finalist and excited to continue building with the LabCentral community.

Find out more

August 2025

We are proud to share that Laurel Biotherapeutics has been awarded the 2025 Mission BioCapital (MBC) Platinum Ticket. This distinguished recognition provides up to $500,000 in pre-seed funding, access to cutting-edge laboratory facilities, specialized discovery services, and world-class mentorship to accelerate our development of first-in-class therapeutics for cardiorenal disease. Mission BioCapital is a leading accelerator of early-stage biotech companies, pairing capital with support, infrastructure, and a network of experienced operators to help teams move faster. We are excited to build alongside the MBC community as we advance our programs.